Theratechnologies (TSE:TH) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Theratechnologies has resubmitted a supplemental Biologics License Application to the FDA for its F8 formulation of tesamorelin, aiming to simplify dosing for HIV patients with excess abdominal fat. The company is addressing previous FDA concerns related to production and immunogenicity risks and expects a decision by March 2025. The new formulation is protected by U.S. patents until 2033.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- BTCC, WGMI: 2 Bitcoin ETFs for Crypto Exposure
- Shareholder Alert for PACS Group, Inc. (NYSE:PACS)
- Netflix Wins Shareholder Lawsuit Alleging Misleading Growth Forecasts
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
